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Objective: This study was undertaken to determine whether low-dose endobronchial
transfer to the donor of the gene for human interleukin 10 would decrease ischemia-
reperfusion injury in lung transplantation.
Methods: Experiments used male Fischer rats. Donor animals underwent right tho-
racotomy. A catheter was introduced into the left main bronchus, and vector was
instilled. Group I (n = 6) received 2 × 107 plaque-forming units of adenovirus
encoding human interleukin 10, group II (n = 6) received an adenovirus control
encoding β-galactosidase, and group III (n = 6) received saline solution. After instil-
lation the left main bronchus was clamped for 60 minutes. Lungs were removed 24
hours later and stored in low-potassium dextran glucose solution for 18 hours before
left lung transplantation. Graft function was assessed at 24 hours immediately
before the animals were killed. Ratio of wet to dry weight and tissue myeloperoxi-
dase activity were measured. Transgenic expression of human interleukin 10 was
evaluated by means of enzyme-linked immunosorbent assay and immunohisto-
chemical assay.
Results: Arterial oxygenation was significantly improved in group I relative to
groups II and III (257.6 ± 59.7 mm Hg vs 114.6 ± 66.9 mm Hg and 118.6 ± 91.1
mm Hg, P = .008 and P = .007, respectively). Neutrophil sequestration, as measured
by myeloperoxidase activity, was also significantly reduced in group I relative to
groups II and III (0.141 ± 0.025 vs 0.304 ± 0.130 and 0.367 ± 0.153 ∆ optical den-
sity units/[min · mg protein], P = .029 and P = .004, respectively). Enzyme-linked
immunosorbent assay and immunohistochemical assay demonstrated the expres-
sion of human interleukin 10 in transfected lungs only.
Conclusions: Low-dose endobronchial transfer to the donor of the gene for human
interleukin 10 ameliorated ischemia-reperfusion injury in rodent lung transplanta-
tion by improving graft oxygenation and reducing neutrophil sequestration. Only 2
× 107 plaque-forming units of adenoviral vector were required for functional trans-
genic expression. Endobronchial gene transfer to lung grafts may be a useful deliv-
ery route even at low doses.
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Lung transplantation is a well-establishedtreatment for end-stage chronic lung dis-ease.1 Two major complications of lungtransplantation that may result in graft dys-function are ischemia-reperfusion injury andgraft rejection. Although these complica-
tions have been studied extensively, they continue to
adversely affect outcome, with no definitive therapy estab-
lished to date.2
Gene therapy has emerged as a new strategy for investi-
gation in the field of thoracic surgery. It has been applied to
the areas of lung transplantation,3 malignant disease,4 and
cystic fibrosis.5 Our laboratory has demonstrated the feasi-
bility of gene therapy in lung transplantation through the
use of a rodent lung transplantation model.
In general there are several strategies for using gene ther-
apy in lung transplantation. Variations include the type of
vector (naked plasmid, liposome, adenovirus, etc), ex vivo
or in vivo gene transfer, transfer to the donor or recipient,
and systemic or localized delivery routes. Endobronchial
gene therapy for the lung graft is an excellent localized
strategy for the treatment of such transplant-related insults
as ischemia-reperfusion injury and graft rejection.
Endobronchial transfection has been performed for acute
rejection,6 but no studies to date have shown a functional
improvement in ischemia-reperfusion injury from the use of
endobronchial transfection.
Interleukin 10 (IL-10) is a potent anti-inflammatory
cytokine that is produced mainly by macrophages and TH2
cells.7 It has been studied for a variety of inflammatory
injuries and may reduce the ischemia-reperfusion injury
after lung transplantation.7 The goal of this study was to
determine whether low-dose endobronchial transfection of
the gene for IL-10 to the donor lung could decrease lung
graft ischemia-reperfusion injury after prolonged cold
ischemia.
Materials and Methods
Animals
Fischer 344 rats (Harlan Sprague Dawley, Inc, Indianapolis, Ind),
weighing 250 to 280 g were used in all experiments. All animal
procedures were approved by the Animal Studies Committee at
Washington University in St Louis. Animals received humane care
in compliance with “Principles of Laboratory Animal Care” for-
mulated by the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals” prepared by
the National Academy of Sciences and published by the National
Institutes of Health (NIH publication 85-23, revised 1985).
Adenoviral Vectors
AdRSVhIL-10 is a replication-deficient recombinant adenoviral
vector encoding the gene for human IL-10 (hIL-10). It was gener-
ated as a homologous recombinant between pAdRSVhIL-10 and
human adenovirus serotype 5 derivative d1309 by standard meth-
ods.8 The bioactivity of this recombinant adenovirus has been con-
firmed by in vitro bioassay.9 The adenovirus used in this study was
purchased from the Gene Therapy Vector Core, College of
Medicine, University of Iowa, Iowa City, Iowa.
First-generation replication-deficient adenovirus serotype 5
carrying the Escherichia coli lacZ gene, which encodes for β-
galactosidase, driven by the constitutive cytomegalovirus pro-
moter (Ad5CMVLacZ). The gene for β-galactosidase is a
nonfunctional reporter gene used as an adenovirus control. It was
purchased from the Gene Therapy Center at the University of
North Carolina, Chapel Hill, NC.
Adenoviral amplification was performed by propagation in 293
cells to obtain high-titer stocks, as determined by the plaque assay
(courtesy of Drs R. Jude Samulski and Douglas McCarty, Gene
Therapy Center Vector Core Facility, University of North
Carolina, Chapel Hill, NC). Purified viral aliquots were stored at
–80°C in 10% glycerol buffered with 10-mmol/L tris(hydrox-
ymethyl)aminomethane, 140-mmol/L sodium chloride, and 1-
mmol/L magnesium chloride. These stocks were thawed and
diluted in 0.1 mL sterile isotonic sodium chloride solution imme-
diately before use.
Experimental Design
Fischer 344 rats were divided into six groups according to the
transfecting vector. Group I (n = 6) and group IV (n = 6) donors
received 2 × 107 plaque-forming units (pfu) of adenovirus encod-
ing hIL-10, group II (n = 6) and group V (n = 3) donors received
2 × 107 pfu adenovirus control encoding β-galactosidase, and
group III (n = 6) and group VI (n = 3) donors received isotonic
sodium chloride solution. The dose of 2 × 107 pfu was chosen on
the basis of preliminary experiments (data not shown).
Transfection with 2 × 106 pfu did not improve lung graft oxy-
genation, whereas transfection with more than 1 × 108 produced
macroscopic lung edema and atelectasis. Endobronchial gene
transfection was performed as follows. Animals were anesthetized
with a subcutaneous injection of ketamine hydrochloride (25
mg/kg) and atropine sulfate (0.25 mg/kg). After endotracheal intu-
bation with a 14-gauge catheter, animals received mechanical ven-
tilation with a small-animal Harvard ventilator (tidal volume 2.5
mL, respiratory rate 60 breaths/min) with 0.75% halothane and
99.25% oxygen. Donors underwent right thoracotomy. A catheter
was introduced through the endotracheal tube into the left main
bronchus, and vector diluted in 0.1 mL sterile isotonic sodium
chloride solution was instilled. After 10 minutes of bilateral venti-
lation following instillation, the left main bronchus was clamped
for 60 minutes at the end-inspiratory phase of mechanical ventila-
tion. After the left main bronchus was unclamped, the right thora-
cotomy was closed and a temporary chest tube was placed. The
chest tube was removed after recovery from anesthesia.
Lungs were harvested 24 hours after gene transfection. Briefly,
after general anesthesia with intraperitoneally administered pento-
barbital (65 mg/kg), mechanical ventilation, systemic hepariniza-
tion (300 units), and median laparosternotomy, donor rat lungs
were flushed through the main pulmonary artery with 20 mL cold
(4°C) low-potassium dextran glucose solution at 20 cm H2O pres-
sure. The heart-lung block was then removed with the lungs
inflated at end-tidal volume.
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In groups I, II, and III, the left lung was isolated and stored at
4°C in low-potassium dextran glucose until implantation. After 18
hours of preservation, recipient animals were anesthetized, intu-
bated with a 14-gauge catheter, and had a left thoracotomy per-
formed. The pulmonary vessels and bronchus were anastomosed
with a modification of the previously described “cuff technique.”10
In groups IV, V, and VI, grafts were harvested from donors and
evaluated for transgenic expression.
Graft Assessment
After 24 hours of reperfusion, recipient animals in groups I, II, and
III were reanesthetized with pentobarbital as described previously.
After tracheostomy, animals received mechanical ventilation with
100% oxygen. The right main bronchus and pulmonary artery
were clamped to isolate the left lung graft. Animals were venti-
lated for 5 minutes at a tidal volume of 1.5 mL, respiratory rate of
100 breaths/min, and positive end-expiratory pressure of 1.0 cm
H2O, followed by arterial blood gas analysis with blood samples
obtained from the ascending aorta. Recipients were then killed
immediately, and the lungs were flushed with 20 mL cold (4°C)
saline solution. Each left lung graft was isolated from the heart-
lung block and divided into sections. The middle third of each lung
graft was frozen in liquid nitrogen for myeloperoxidase activity
measurement. The lower third of each graft was weighed, dried at
80°C for 48 hours, and then reweighed for calculation of the wet
to dry weight ratio.
Transgenic Expression of hIL-10
Transgenic expression of hIL-10 was evaluated in groups IV, V,
and VI with enzyme-linked immunosorbent assay (ELISA) and
immunohistochemical assay.
Myeloperoxidase Activity
Quantitative myeloperoxidase activity was determined as previ-
ously described.11 Optical density was measured at 460 nm with a
spectrophotometer (model PMQ II; Carl Zeiss, Oberkochen,
Germany). Color development was linear from 5 minutes to 20
minutes. One unit of enzyme activity was defined as 1.0 optical
density units per minute per milligram of tissue protein at room
temperature.
ELISA
Lung specimen samples were homogenized with a lysis solution
consisting of 100 mmol/L of potassium phosphate dibasic, pH 7.8,
including 0.2% of Triton X-100 (Fisher Scientific Worldwide,
Laboratory Projects Division, Springfield, NJ), and the protease
inhibitor Complete Mini (Hoffmann-LaRoche Inc, Nutley, NJ).
After 15 minutes of extraction at room temperature, the extraction
was clarified by centrifugation at 11,000g for 10 minutes at 4°C
and stored at –80°C until measurement. The hIL-10 ELISA kit
was purchased from R&D Systems, (Minneapolis, Minn), and
there is no cross-reactivity between hIL-10 and rat IL-10 proteins.
Optical density was determined with an Ultra Microplate Reader
(EL808; Bio-Tek Instruments, Inc, Winooski, Vt) set at 450 nm.
The wavelength correction was performed under subtraction read-
ings at 540 nm from the readings at 450 nm. The extract was sub-
sequently assayed for total soluble protein (picograms per
milligram total protein) by the method of Pierce Laboratories
(Rockford, Ill).12
Immunohistochemical Assay
Tyramide Signal Amplification Biotin System kits (NEN Life
Science Products, Inc, Boston, Mass) were used for immunohisto-
chemical assay. Briefly, lungs were perfused with 20 mL isotonic
sodium chloride solutions and 20 mL HistoChoice (Amresco Inc,
Solon, Ohio). Specimens were fixed, cut, mounted, deparaffinized,
and then treated with Dako Target Retrieval Solution (DAKO
Corporation, Carpinteria, Calif) followed by 3% hydrogen perox-
ide in methanol. The sections were then incubated with an FcγII
receptor blocker (purified anti–rat CD32; BD PharMingen, San
Diego, Calif) and with Super Block Blocking Buffer (Pierce
Chemical Company, Rockford, Ill) including 1% bovine serum
albumin and 1% normal goat serum, followed by TNB Blocking
Buffer in Tyramide Signal Amplification kits. After 60 minutes at
room temperature the sections were incubated with a biotinylated
rat anti–human IL-10 and viral IL-10 monoclonal antibody (BD
PharMingen) at 1:25 dilution in TNB Blocking Buffer at 4°C
overnight. They were then incubated with streptavidin–horserad-
ish peroxidase followed by biotinyl tyramide solution. The strep-
tavidin–horseradish peroxidase and biotinyl tyramide solution
procedures were repeated. The slides were incubated with strepta-
vidin–alkaline phosphatase (NEN Life Science Products). Specific
binding was detected with the BCIP/NBT substrate working solu-
tion (Vector Laboratories, Inc, Burlingame, Calif) containing 5-
mmol/L levamisole (Vector Laboratories) until detection of
staining. The slides were then counterstained with nuclear fast red,
dehydrated, mounted, and coverslipped.
Figure 1. Mean arterial oxygen tension of isograft with inhaled
100% oxygen under right hilar crossclamping. Group I (transfected
with gene for hIL-10) had PaO2 superior to those of groups II (trans-
fected with gene for β-galactosidase) and III (saline control).
Differences between group I and groups II and III (257.6 ± 59.7 vs
114.6 ± 66.9 and 118.6 ± 91.1 mm Hg, respectively) were statistically
significant. Bar heights represent mean; error bars represent SD.
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Statistical Analysis
All values are described as mean ± SD. Data not normally distrib-
uted were analyzed after logarithmic correction. One-way analysis
of variance with pairwise comparison by the Fisher positive least
significant difference method was used to compare overall differ-
ences among groups.
Results
Isolated Lung Isograft Gas Exchange
PaO2 levels for group I transfected with hIL-10 were signif-
icantly higher than in groups II and III (Figure 1). Mean
PaCO2 levels in group I were significantly lower than in
group II but not in group III (28.2 ± 6.7 vs 41.9 ± 8.6 and
35.9 ± 11.0 mm Hg, P = .018 and .158, respectively, by
analysis of variance).
Wet to Dry Weight Ratio
The wet to dry ratio is an indicator of tissue edema. Group
I lungs had lower wet to dry ratios, reflecting less tissue
edema, than either group II or III lungs (Figure 2).
Myeloperoxidase Activity
Myeloperoxidase activity is a reflection of tissue neutrophil
sequestration.13 Myeloperoxidase levels were significantly
reduced in group I lungs (Figure 3).
ELISA for hIL-10
The extracts derived from lung homogenate centrifugation
were used for the measurement of hIL-10 in lung tissue.
Figure 2. Wet to dry ratio of isograft. A trend toward significance
existed in differences between mean wet to dry weight ratios in
group I (transfected with gene for hIL-10) and in groups II (trans-
fected with gene for β-galactosidase) and III (saline control).
Ratios of groups I, II, and III were 5.69 ± 0.71, 7.04 ± 1.73, and 7.01
± 1.43, respectively. Bar heights represent mean; error bars repre-
sent SD.
Figure 3. Myeloperoxidase of reperfused lung isograft.
Myeloperoxidase activity, reflected by tissue neutrophil seques-
tration and immigration, was significantly reduced in group I
(transfected with gene for hIL-10) relative to groups II (transfected
with gene for β-galactosidase) and III (saline control). Activities
were 0.141 ± 0.025, 0.304 ± 0.130, and 0.367 ± 0.153 ∆ optical den-
sity units (OD)/min · mg protein. Bar heights represent mean; error
bars represent SD.
Figure 4. ELISA for hIL-10 in lung isograft without reperfusion.
Superior expression of hIL-10 was observed in 3 hIL-10–trans-
fected lung specimens obtained just after explantation (26.2 ± 15.2
pg/mg total protein for group IV, transfected with gene for hIL-10)
but was not detected in groups V (transfected with gene for β-
galactosidase) and VI (saline control). Statistically significant dif-
ferences existed between group IV and groups V and VI. Three
specimens from group IV lungs transfected with hIL-10 were pre-
served 18 hours after explantation and were also used for mea-
surement; their value was 21.7 ± 4.1 pg/mg total protein. Bar
heights represent mean; error bars represent SD.
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Figure 5. Immunohistochemical assay for hIL-10 in rat lungs without reperfusion. Characteristic patchy staining was
observed in the alveolar areas of hIL-10–transfected lungs (A, magnification ×20; E, magnification ×200). Bronchial
epithelial, bronchiolar epithelial, and alveolar cells were stained, but vessel endothelial, smooth muscle, and inter-
stitial tissue cells were not stained (C, magnification ×100). B, D, and F are cells stained without cytokine antibodies
that served as negative controls.
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These lung specimens were not reperfused but stored at
–80°C just after harvest. Transgenic expression of hIL-10
was observed in group IV lung specimens, which were
obtained just after harvest and also after 18 hours of preser-
vation (Figure 4).
Immunohistochemical Assay for hIL-10
Positive immunohistochemical staining for hIL-10 was
observed in hIL-10–transfected lungs. Alveolar areas
showed patchy staining (Figure 5, A and E). The distribu-
tion of expression was increased in the hilar area relative to
the peripheral lung. Staining could be seen in bronchial
epithelial, bronchiolar epithelial, and alveolar cells but was
not seen in vessel endothelial, smooth muscle, or interstitial
tissue cells (Figure 5, C). As expected, no hIL-10 staining
was present in lungs transfected with either β-galactosidase
or saline solution, because these vectors did not contain the
gene for hIL-10.
Discussion
The best method of delivering gene therapy in lung trans-
plantation remains to be determined. Both systemic and
local strategies have been demonstrated to reduce acute
lung injury.6,13-17 Intravenous and intramuscular transfec-
tion are systemic delivery routes. Endobronchial, intra–pul-
monary artery and intra–pulmonary vein transfection are
localized delivery routes. Our laboratory has reduced acute
rejection with both systemic13 and localized6,14 gene deliv-
ery. We have also demonstrated that systemic intravenous
transfection of functional genes for heat shock protein 70,15
endothelial nitric oxide synthase,16 and hIL-1017 to the
donor attenuates ischemia-reperfusion injury. Our experi-
ence to date has shown that intravenous gene delivery
requires at least 5 × 109 pfu of adenoviral vector. The effi-
cacy of localized endobronchial gene transfer in reducing
ischemia-reperfusion injury has not been previously
demonstrated. In this study endobronchial hIL-10 delivery
with a low dose of an adenoviral vector (2 × 107 pfu) signif-
icantly reduced ischemia-reperfusion injury. Endobronchial
gene transfer thus reduced the quantity of vector needed
250-fold.
The pathophysiology of ischemia-reperfusion injury has
been under intense investigation. The numerous pathologic
factors involved include endothelial cell injury, neutrophil
activation, platelet activation, oxygen-derived free radicals,
and various cytokines.18,19 IL-10 is a potent anti-inflamma-
tory cytokine that is secreted primarily by macrophages and
TH2 cells.7 Recent reports indicate that recombinant IL-10
reduces ischemia-reperfusion injury in the hind limb,20
heart,21 and lung.22 This cytokine is a key factor in the
ischemia-reperfusion injury cascade.
In this study overexpression of hIL-10 resulted in physi-
ologic lung graft improvement and reduced ischemia-reper-
fusion injury. The mechanism for this improvement may be
that gene transfer produced hIL-10 protein, which in turn
led to a favorable anti-inflammatory environment. In
assessment of the isolated lung graft, gas exchange is the
most important and notable parameter. Lung graft oxygena-
tion was almost doubled in hIL-10–transfected lungs rela-
tive to control lungs. In addition, hIL-10–transfected lungs
demonstrated significantly lower neutrophil sequestration,
as shown by myeloperoxidase activity. Other data, such as
carbon dioxide levels and wet to dry ratio measurements,
revealed trends toward physiologic improvement in hIL-
10–transfected lungs.
Gene transfection was performed in vivo to the donor lung
to enhance hIL-10 expression during cold ischemia and
reperfusion. Ex vivo transfection is easier to perform than in
vivo transfection, similar to performing a procedure on the
side table in the clinical setting. However, we have previously
demonstrated that ex vivo transfection followed by cold
preservation does not produce gene expression at the time of
reperfusion.23 Because reperfusion injury begins immedi-
ately, ex vivo transfection is not beneficial in this setting. Ex
vivo transfection should therefore continue to be considered
as a potential strategy for the reduction of graft rejection14 but
not for amelioration of ischemia-reperfusion injury.
Cassivi and colleagues24 revealed the potential for endo-
bronchial gene therapy in lung transplantation. In their
study in vivo endobronchial transfection of the donor pro-
duced β-galactosidase protein expression both at the time of
reperfusion and 2 hours after transplantation. According to
ELISA data in our study, hIL-10 protein was successfully
expressed in lungs transfected with hIL-10 at the time of
removal and 18 hours after cold preservation. Therefore the
hIL-10 protein expressed in the donor before explantation
would remain intact during cold storage and would be
effective at the start of graft reperfusion, when reperfusion
injury begins. The in vivo protocol used in this experiment
transfected the donor 24 hours before lung removal. This is
clinically feasible for living-related donor transplantation
but is not ideal for most conventional lung transplants.
Systemic gene delivery requires large amounts of vector,
and the systemic side effects are not clear. This study
demonstrates that localized endobronchial gene delivery
requires significantly less adenovirus vector. Endobronchial
gene delivery is a uniquely graft-targeted transfection strat-
egy for lung transplantation. The merits of endobronchial
transfection are that it is easy to perform, may be minimally
invasive, and only transfects the lung. Endobronchial
gene transfer probably works in a paracrine manner. It
transfects bronchial epithelium without significant sys-
temic expression in heart, liver, native right lung, or
plasma.6,24,25 Endobronchial instillation to lung grafts
thus may provide an effective, organ-selective transfec-
tion system for lung grafts.
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Potential complications of endobronchial gene delivery
include heterogeneous distribution of gene expression and
local inflammation.26 Immunohistochemical results in this
study showed greater distribution of gene expression in the
hilar area than in the peripheral area, with patchy alveolar
staining. The heterogeneous distribution of gene expression
probably reflects heterogeneous transfection. An aerosomal
vector solution may provide an answer to the heterogeneous
distribution problem, and studies are ongoing to develop
this method. Local inflammation may be due to the hetero-
geneous volume of vector solution or direct toxicity of the
adenovirus vector,27 or gene transfer with adenoviral vec-
tors may incite a host immune response, resulting in dose-
dependent inflammation.26 It is possible that the transfected
lung would have an inflammatory response, such as pneu-
monia, atelectasis, or edema, after endobronchial transfec-
tion. In fact, some inflammatory cells in the alveoli were
observed in our immunohistochemical slides.
The protein expression of the transfected gene is also
dose dependent.28 In this study we improved the expression
of hIL-10 by clamping the bronchus during adenovirus
instillation. Previous work in our laboratory indicates that
clamping the bronchus during endobronchial transfection
improves gene expression. The mechanism by which
bronchus clamping can increase gene expression was found
to be increased exposure time.29 We speculate that clamp-
ing the bronchus reduces the amount of vector that would
be exhaled, increases epithelial contact with the vector by
decreasing respiratory movements, increases lung surface
area by maintaining lung hyperinflation, and increases pos-
itive airway pressure at end-inspiration to promote adenovi-
ral vector uptake by airway epithelial cells. In this study,
graft function did not improve when 60 minutes of left main
bronchus clamping was omitted (data not shown). We there-
fore believe that clamping the bronchus is an important part
of this transfection strategy. Endobronchial transfection
with this technique reduced the amount of adenovirus vec-
tor needed to a 250th of that needed with intravenous trans-
fection.15-17 Using less vector decreases costs, reduces local
inflammation, and reduces viral antigenicity in cellular and
humoral immune responses.30 The balance between effi-
cient gene transfection and airway inflammation warrants
further investigation.
In the study of gene transfer for lung transplantation, the
connection between gene expression and physiologic
improvement is crucial. Transgenic expression without
physiologic improvement probably occurs with low expres-
sion of transgenic proteins. However, the increased quantity
of vector required for high protein expression increases vec-
tor-related side effects and thus may not lead to physiologic
improvement. We therefore continue to search for the gene
transfection strategy with the fewest and least severe side
effects, the highest transfection efficiency, and the highest
production of functional protein resulting in physiologic
improvement so that we eventually may apply this strategy
in the clinical setting.
In conclusion, in vivo endobronchial transfection of the
gene for hIL-10 in the donor lung ameliorates ischemia-
reperfusion injury in rodent lung transplantation. Lung
grafts transfected with the gene for hIL-10 showed
improved graft oxygenation and reduced neutrophil seques-
tration. In addition, the localized endobronchial transfection
strategy used 250-fold less vector than other reported routes
of adenovirus-mediated gene transfer. Endobronchial gene
transfer to lung grafts is a potential strategy for clinical lung
transplantation.
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